Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 19;59(6):e00158-21.
doi: 10.1128/JCM.00158-21. Print 2021 May 19.

Comparative Performance of Latest-Generation and FDA-Cleared Serology Tests for the Diagnosis of Chagas Disease

Affiliations

Comparative Performance of Latest-Generation and FDA-Cleared Serology Tests for the Diagnosis of Chagas Disease

Emily A Kelly et al. J Clin Microbiol. .

Abstract

Confirmed diagnosis of chronic Chagas disease (CD) requires positive results by two different IgG serology tests. Variable sensitivity has been reported among tests and in different geographic regions. Inadequate specificity presents a particular challenge in low-prevalence settings such as the United States. This study provides a direct comparison of the latest-generation IgG serology assays with four previously assessed FDA-cleared tests. Seven hundred ten blood donor plasma specimens were evaluated by Wiener Lisado and Wiener v.4.0 enzyme-linked immunosorbent assays (ELISAs) and Abbott PRISM Chagas chemiluminescent assay (ChLIA). Sensitivity and specificity were assessed relative to infection status as determined by the original blood donation testing algorithm. All three latest-generation assays demonstrated 100% specificity (95% confidence interval [CI], 98.6 to 100.0). Wiener Lisado, Wiener v.4.0, and Abbott PRISM had sensitivities of 97.1% (95% CI, 95.1 to 98.4), 98.9% (95% CI, 97.4 to 99.6), and 95.5% (95% CI, 93.2 to 97.3), respectively. As with previously evaluated FDA-cleared tests, all three assays had the highest reactivity and sensitivity in samples from donors born in South America and lowest reactivity and sensitivity in specimens from those born in Mexico, with intermediate results in specimens from Central American donors. Wiener v.4.0 had the highest diagnostic sensitivity in all comparisons. Our findings suggest that the latest-generation CD serology tests could improve diagnostic sensitivity without affecting specificity.

Keywords: Chagas disease; Trypanosoma cruzi; clinical diagnostics; diagnostics; serology.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Comparison of optical density values for latest-generation IgG serological assays by region of birth. Wiener Lisado displayed a median S/CO of 6.95 (interquartile range [IQR], 6.05 to 7.38) for samples of donors born in South America, 4.89 (IQR, 3.96 to 5.65) for samples of donors born in Central America, and 2.68 (IQR, 2.28 to 3.34) for samples of donors born in Mexico. Wiener v.4.0 displayed a median S/CO of 5.78 (IQR, 5.43 to 6.72) for samples of donors born in South America, 5.20 (IQR, 4.69 to 6.04) for samples of donors born in Central America, and 3.67 (IQR, 3.02 to 4.07) for samples of donors born in Mexico. Abbott PRISM displayed a median S/CO of 8.92 (IQR, 7.64 to 9.71) for samples of donors born in South America, 7.97 (IQR, 6.71 to 8.59) for samples of donors born in Central America, and 5.09 (IQR, 4.42 to 6.60) for samples of donors born in Mexico. Bar and whiskers represent median with interquartile range. ns, P ≥ 0.05; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

References

    1. Cantey PT, Stramer SL, Townsend RL, Kamel H, Ofafa K, Todd CW, Currier M, Hand S, Varnado W, Dotson E, Hall C, Jett PL, Montgomery SP. 2012. The United States Trypanosoma cruzi infection study: evidence for vector-borne transmission of the parasite that causes Chagas disease among United States blood donors. Transfusion 52:1922–1930. doi:10.1111/j.1537-2995.2012.03581.x. - DOI - PubMed
    1. Bern C, Messenger LA, Whitman JD, Maguire JH. 2019. Chagas disease in the United States: a public health approach. Clin Microbiol Rev 33:e00023-19. doi:10.1128/CMR.00023-19. - DOI - PMC - PubMed
    1. World Health Organization. 2015. Chagas disease in Latin America: an epidemiological update based on 2010 estimates. Wkly Epidemiol Rec 90:33–44. - PubMed
    1. Bern C, Montgomery SP. 2009. An estimate of the burden of Chagas disease in the United States. Clin Infect Dis 49:e52–e54. doi:10.1086/605091. - DOI - PubMed
    1. Nunes MCP, Beaton A, Acquatella H, Bern C, Bolger AF, Echeverría LE, Dutra WO, Gascon J, Morillo CA, Oliveira-Filho J, Ribeiro ALP, Marin-Neto JA, American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, Council on Cardiovascular and Stroke Nursing, Stroke Council . 2018. Chagas cardiomyopathy: an update of current clinical knowledge and management: a scientific statement from the American Heart Association. Circulation 138:e169–e209. doi:10.1161/CIR.0000000000000599. - DOI - PubMed

Publication types

Substances